Impact of community pharmacist antibiotic prescribing for minor ailments: an interrupted time series analysis Authors: Valerie Leung, Bradley Langford, Kevin A Brown, Dorsa Ghahramani, Julie Hoang, Anjali Oberai, Mina Tadrous, Nick Daneman, Kiran Saqib, Kevin Schwartz Published: 2025 ABSTRACT Abstract AbstractObjectiveOn 1 January 2023, Ontario expanded pharmacists’ scope of practice, allowing them to prescribe medications for 13 minor ailments, including antibiotics for uncomplicated urinary tract infections (UTIs) and Lyme disease (LD) prophylaxis. This study evaluates pharmacist billing claims and pharmacist and physician antibiotic-prescribing rates before and after policy implementation.DesignAn interrupted time series analysis measuring changes in prescribing trends post-implementation.SettingThis retrospective study analysed visit claims and antibiotic prescribing for UTIs and LD prophylaxis before policy implementation (2022) and after (2023–2024) in Ontario.ParticipantsData from OntariansPrimary outcome measuresPrescribing rates were standardised per 1000 inhabitants, stratified by provider type, patient age and sex, and antibiotic type.ResultsIn 2023 and 2024, pharmacists submitted over 1.47 million minor ailment claims, with UTIs making up 34.2% and LD prophylaxis making up 2.6% of total claims. UTI claims were primarily for women aged 25–64, and LD prophylaxis peaked in spring and fall. Pharmacist prescribing of eligible urinary drugs in females increased by 33.3 per 1000 person-years (95% CI 30.8 to 36.6) while physician prescribing decreased by 23.3 (95% CI −32.2 to −15.3), leading to a modest net increase of 10.1 (95% CI 0.0 to 18.7). Pharmacist prescribing of doxycycline was offset by decreased physician prescribing, resulting in no change (0.0, 95% CI −1.0 to 0.9). Pharmacist prescribing for other antibiotics was low over the study timeframe, while physician prescribing increased, which was driven by increased prescribing of penicillins and macrolides.ConclusionThere was a clear increase in pharmacist prescribing for eligible drugs in the eligible population post-policy implementation. Pharmacists in Ontario appear to be prescribing within policy limits for uncomplicated UTIs and LD prophylaxis.Keywords: Antibiotics, Pharmacists, Primary Health Care, Health policy, Urinary tract infections STRENGTHS AND LIMITATIONS OF THIS STUDY Use of antibiotic-prescribing data to evaluate the impact of policy change on overall community antibiotic use. Use of antibiotic-prescribing data to evaluate the impact of policy change on overall community antibiotic use. Use of interrupted time series models accounting for underlying time trends and seasonality to evaluate antibiotic use. Use of interrupted time series models accounting for underlying time trends and seasonality to evaluate antibiotic use. Lack of indication and duration of therapy in prescription data limit the assessment of antibiotic-prescribing appropriateness. Lack of indication and duration of therapy in prescription data limit the assessment of antibiotic-prescribing appropriateness. Introduction In Canada, pharmacists in 10 provinces and one territory are now allowed to prescribe treatments for minor ailments, which are health conditions that can be self-diagnosed and managed with minimal treatment and follow-up.1 The basis for minor ailment programmes in Canada is to use pharmacists’ expertise and availability to improve access to care while reducing non-urgent visits to physicians and emergency departments; however, the conditions that are included vary between jurisdictions.2 Since Alberta first implemented independent pharmacist prescribing in 2007, other jurisdictions have gradually implemented pharmacist prescriptive authority for minor ailments, with many expanding the number of conditions over time.3 Some provinces, including Ontario, restrict prescribing to a defined list of agents for the minor ailment, while others, such as Alberta, allow pharmacists to prescribe any Schedule one drugs if clinically appropriate.3 4 Patient eligibility also varies by province, with differences in age limits, clinical exclusions and other requirements. Reflecting differences in programme scope, educational requirements also vary with some provinces like Alberta and Saskatchewan having extensive clinical training requirements and others like New Brunswick requiring participation in an orientation session about changes in legislation and documentation requirements.5 In January 2023, pharmacists in Ontario gained the authority to prescribe medications for 13 minor ailments including selected oral antibacterials for uncomplicated urinary tract infection (UTI) treatment and Lyme disease (LD) prophylaxis following a high-risk tick bite. The other conditions were allergic rhinitis, candidal stomatitis, conjunctivitis, dysmenorrhoea, gastro-oesophageal reflux disease, haemorrhoids, herpes labialis, impetigo, insect bites and urticaria, and musculoskeletal sprains and strains.6 Prior to offering minor ailment service, pharmacists were required to complete a mandatory orientation module about ethical, legal and professional obligations.4 In October 2023, this was expanded to include six additional conditions which were acne, canker sores, Diaper dermatitis, nausea and vomiting in pregnancy, pinworms and threadworms, and vulvovaginal candidiasis. For UTI, prescribing by pharmacists is limited to nitrofurantoin, fosfomycin, sulfamethoxazole and/or trimethoprim for individuals presenting with symptoms of acute cystitis without complicating features that would require referral (eg, male sex, pregnancy, age <12 years).7 8 Pharmacists are also authorised to prescribe a single dose of doxycycline following a tick bite for asymptomatic individuals at high risk of developing LD.7 9 This service is funded by the Ministry of Health for eligible individuals, and pharmacies can submit claims for virtual or in-person visits whether or not a prescription is issued.6 Previous research in other jurisdictions has demonstrated pharmacist antibiotic prescribing to be safe, effective and generally appropriate.10 A study of 750 patients with uncomplicated UTIs in New Brunswick found that pharmacist-led management led to high patient satisfaction, symptom resolution and similar clinical cure rate as for physician-led management and that pharmacist prescribing was highly concordant with clinical guidelines.11 12 A retrospective cohort study in Nova Scotia evaluating doxycycline prescribing by pharmacists for LD chemoprophylaxis found that pharmacists became the primary prescribers for this indication after policy implementation.13 However, concerns have been raised about the potential risks of this new practice in Ontario, including overprescribing by pharmacists exacerbating antimicrobial resistance.14 15 To our knowledge, very few studies have examined the impact of pharmacist prescribing on overall community antimicrobial use, which is a key driver of antimicrobial resistance. The objectives of this study were to describe pharmacist visits for UTI and tick bites and compare pharmacist, physician and total antibiotic-prescribing rates before and after policy implementation. Methods Study design and setting This was a retrospective interrupted time series (ITS) and descriptive observational study that took place in Ontario, Canada’s most populous province with over 15 million inhabitants. As the policy was implemented on 1 January 2023, the pre-intervention period was 1 January to 31 December 2022 (12 months), and the post-intervention period was 1 January 2023 to 31 December 2024 (24 months). Patient and public involvement Patients or the public were not involved in the design, conduct, reporting or dissemination plans of our research. Data sources Minor ailments billing claims to the Ministry of Health for UTI and tick bites for the post-implementation period (1 January 2023 to 31 December 2024) were used to describe patient and visit characteristics. We identified these based on product identification number submitted to the Ontario Drug Benefit programme. These data are securely linked using unique, encoded identifiers and analysed at ICES (formerly known as the Institute for Clinical Evaluative Sciences) and are routinely used for health services research. The Geographic Prescription Monitor (GPM) database from IQVIA was used for monthly community antibiotic prescription data for the pre-intervention (1 January 2022 to 31 December 2023) and post-implementation periods. GPM is a prospectively collected administrative database based on prescription data from a sample of Ontario pharmacies accounting for approximately 78% of all dispensed medications which is then projected to represent 100% of all dispensed medications in the province. To do this, IQVIA uses a proprietary geospatial algorithm that incorporates additional sales and insurance claims data as well as geographical information from pharmacies not initially captured. Although the specific methodology used by IQVIA is proprietary, the data have been internally validated by IQVIA. The dataset used for this study includes monthly counts of new prescriptions (ie, excluding refills) issued by general practice physicians and pharmacists. To standardise prescribing trends, rates were calculated using population estimates for Ontario for the respective years per 1000 inhabitants using census data.16 Outcomes The primary outcomes of interest were pharmacist and physician antibiotic-prescribing rates pre- and post-policy implementation and pharmacist visits for UTI and tick bites post-implementation. Prescribing rates per 1000 inhabitants were determined for eligible urinary antibiotics among women (nitrofurantoin, fosfomycin, sulfamethoxazole and/or trimethoprim), urinary fluoroquinolones (FQ) among women (ciprofloxacin, norfloxacin) and doxycycline regardless of sex. For urinary antibiotics, we further stratified by patient sex because male sex is generally considered a complicating factor and pharmacists are only authorised to prescribe for uncomplicated UTI, which typically occurs in females by definition (ie, eligible population).17 To evaluate overall antibiotic use, we also compared prescribing rates for other antibiotics for which pharmacists are not authorised to prescribe and total antibiotics (ie, all oral J01 systemic antibacterial agents).18 Analysis We analysed pharmacist billing claims and antibiotic prescription data separately. The number of claims for UTI and tick bites was reported by month, patient age groups and sex, whether the visit was virtual or in-person, and if a prescription was provided. The prescription data were reported annually and stratified by the categories described above. An ITS analysis was performed to evaluate the association between policy implementation and the annual rate of antibiotic prescribing. The ITS was implemented using a negative binomial regression of the prescription counts, with an offset corresponding to the log-population for each of the three drugs and for pharmacists and physicians separately, for a total of six models. For pharmacists, the impact of the intervention was easy to identify; it was equal to the difference between the pre-intervention prescribing rate (essentially 0) and the post-intervention prescribing rate. For physicians, the impact of the intervention was hypothesised to be proportional to the increase in pharmacist prescribing; to achieve this, a covariate was measured equal to the pharmacist monthly prescribing rate for a given drug, divided by the maximum prescribing rate in the study period. This covariate was subsequently entered into the regression models for pharmacist prescribing, along with linear time trend and a cyclic cubic spline to capture residual seasonal trends. Each ITS model was used to measure the relative change as well as the absolute change in prescribing, using marginal standardisation. Statistical analysis was conducted using R version 4.4.3 and the mgcv package.19 Ethics approval This project was reviewed and approved by Public Health Ontario’s Ethics Review Board (file no. 2024–021.02). Results Minor ailments service claims During the post-implementation period, there were 502 833 claims for UTI and 37 798 claims for tick bites, which represented 34.2% and 2.6% of all minor ailment claims, respectively (n=1,470,084). For UTI, there was a gradual increase in claims over time with over ~20 000 per month after the first 6 months (range 15 826–25,955). For tick bites, a seasonal pattern was observed with a higher frequency of claims from April to July and in October and November (figure 1). Total number of minor ailments service claims for uncomplicated UTI and tick bites (1 January 2023 to 31 December 2024). UTI, urinary tract infection. When looking at the first claim of each minor ailment type for an individual patient per year, roughly 65% of patients assessed for UTI were between the ages of 25 and 64, 23% were 65 years of age or older and 99% were female. 83% were in-person visits and 87.9% resulted in a prescription. For tick bites, about 50% of patients were 25–64 years old, 30% were 65 or older and 45% were female. 88% were in-person visits and 85.8% of visits resulted in a prescription (table 1). Table 1Patient and visit characteristics for urinary tract infection and tick bite claims*Uncomplicated UTIn (%)Tick biten (%)2023n=1 93 1982024n=2 29 702Totaln=4 22 9002023n=13 3062024n=21 866Totaln=35 172Age group 0–14883(0.5%)913(0.4%)1796(0.4%)1405 (10.6%)2565 (11.7%)3970(11.3%) 15–2422 593 (11.7%)27 415 (11.9%)50 008(11.8%)670 (5.0%)1147 (5.2%)1817(5.2%) 25–4464 797 (33.5%)78 130 (34.0%)142 927 (33.8%)2620 (19.7%)4260 (19.5%)6880(19.6%) 45–6460 550 (31.3%)70 861 (30.8%)131 411 (31.1%)4486 (33.7%)7321 (33.5%)11 807(33.6%) 65+44 375 (23.0%)52 224 (22.7%)96 599(22.8%)4125 (31.0%)6561 (30.0%)10 686(30.4%) Missing–159(0.1%)159(0.04%)–12 (0.1%)12(0.03%)Sex Female191 087 (98.9%)227 868(99.2%)418 955 (99.1%)5916 (44.5%)9870 (45.1%)15 786(44.9%) Male2111 (1.1%)1675 (0.7%)3786(0.9%)7390 (55.5%)11 984 (54.8%)19 374(55.1%) Missing–159(0.1%)159(0.04%)–12(0.1%)12(0.03%)Visit type In-person157 698 (81.6%)196 788 (85.7%)354 486 (83.8%)11 401 (85.7%)19 545 (89.4%)30 946(88.0%) Virtual35 500 (18.4%)32 914 (14.3%)68 414(16.2%)1905 (14.3%)2321 (10.6%)4226(12.0%)Visit outcome No prescription issued26 064 (13.5%)25 316 (11.0%)51 380(12.1%)2205 (16.6%)2778 (12.7%)4983(14.2%) Prescription issued167 134 (86.5%)204 386 (89.0%)371 520 (87.9%)11 101 (83.4%)19 088 (87.3%)30 189(85.8%)*Based on first claim of each minor ailment type for an individual patient per year.UTI, urinary tract infection. Patient and visit characteristics for urinary tract infection and tick bite claims* Based on first claim of each minor ailment type for an individual patient per year. UTI, urinary tract infection. Antibiotic prescribing rates Although the pharmacist prescription rates per 1000 inhabitants for eligible urinary antibiotics in females increased from 0.25 (2022) to 30.08 (2023) and 37.27 (2024), physician prescription rates for this group decreased from 93.61 (2022) to 75.89 (2023) and 67.32 (2024). In males, pharmacist prescription rates for eligible urinary antibiotics remained less than 1 (0.13–0.67), and physician prescription rates were between 13.98 and 15.34 over 3 years. Pharmacist and physician prescribing for urinary FQ (ie, ciprofloxacin, norfloxacin) remained relatively stable from 2022 to 2024 with the pharmacist prescribing rate being close to zero and the physician prescribing rate being about 20 prescriptions per 1000 inhabitants per year (table 2). Table 2Oral antibiotic prescriptions per 1000 inhabitantsPharmacistsPhysicians*Year202220232024202220232024All antibiotics1.6317.8421.96295.46315.55333.82Doxycycline (both sexes)†0.070.951.4812.2513.2015.64Eligible urinary antibiotics for eligible population (female sex)† Nitrofurantoin0.1323.9223.0159.9944.0633.09 TMP/SMX & TMP‍0.102.606.4418.0516.9018.21 Fosfomycin‍0.023.567.8215.5714.9316.03 Total‍0.2530.0837.2793.6175.8967.32Urinary fluoroquinolones for eligible population (female sex) Ciprofloxacin0.060.130.1220.3819.3019.58 Norfloxacin‍0.000.010.011.221.000.96Eligible urinary antibiotics for ineligible population (male sex) Nitrofurantoin0.020.250.415.345.954.71 TMP/SMX & TMP‍0.100.150.197.507.988.59 Fosfomycin‍0.010.030.071.131.401.57 Total‍0.130.430.6713.9815.3414.87Urinary fluoroquinolones for ineligible population (male sex) Ciprofloxacin0.060.070.0714.5914.7314.21 Norfloxacin‍0.000.010.010.390.380.35Other antibiotics (both sexes) Penicillin without β-lactamase inhibitors0.490.730.5174.5389.1792.86 Penicillin with β-lactamase inhibitors‍0.120.140.1830.2436.8241.86 First-generation cephalosporins‍0.110.150.1437.1838.6838.72 Second- and third-generation‍ cephalosporins‍0.110.100.099.869.439.43 Macrolides‍0.320.320.3847.0252.2663.52 Third-generation fluoroquinolones0.060.070.055.676.006.70 Clindamycin‍0.020.030.024.324.213.99 Linezolid‍0.000.000.000.010.020.02 Minocycline‍0.010.010.011.371.151.01 Tetracycline‍0.020.020.021.291.321.36 Total‍1.261.571.40211.49239.06259.47*General Practice/Family Medicine specialty only (excludes physician specialists, dentists and other healthcare providers)†Pharmacists authorised to prescribeTMP/SMX & TMP, trimethoprim-sulfamethoxazole and trimethoprim. Oral antibiotic prescriptions per 1000 inhabitants General Practice/Family Medicine specialty only (excludes physician specialists, dentists and other healthcare providers) Pharmacists authorised to prescribe TMP/SMX & TMP, trimethoprim-sulfamethoxazole and trimethoprim. The ITS shows that pharmacist prescribing increased by 33.3 per 1000 inhabitants per year (95% CI 30.8 to 36.6) for eligible urinary antibiotics in females, physician prescribing for the same group decreased by 23.3 (95% CI −32.2 to −15.3) (figure 2). With respect to urinary FQ for females, pharmacist prescribing increased by 0.1 (95% CI 0.1 to 0.1), whereas physician prescribing decreased by 2.22 (95% CI −4.4 to to −0.3). The net change was an increase of 10.1 prescriptions per 1000 inhabitants per year (95% CI 0.0 to 18.7) for eligible urinary antibiotics in females and a decrease of 2.1 (95% CI −4.3 to −0.2) for urinary FQ in females. Pharmacist and physician annual antibiotic-prescribing rates for doxycycline, eligible urinary antibiotics and urinary fluoroquinolones (FQ)*. *UTI antibiotics: nitrofurantoin, fosfomycin, sulfamethoxazole and/or trimethoprim; urinary FQ: ciprofloxacin, norfloxacin. Doxycycline-prescribing rates increased from 0.07 (2022) to 0.95 (2023) and 1.48 (2024) per 1000 inhabitants per year for pharmacists and from 12.25 (2022) to 13.20 (2023) and 15.64 (2024) per 1000 inhabitants per year for physicians (table 2). The ITS shows that pharmacist prescribing increased by 1.1 per 1000 inhabitants per year (95% CI 0.8 to 1.7) and that physician prescribing decreased by 1.1 per 1000 inhabitants per year (95% CI −2.2 to −0.2), resulting in no net change (0.0, 95% CI −1.0 to 0.9) in doxycycline prescribing (figure 2). The total prescribing rates for all antibiotics (eligible urinary antibiotics, urinary FQ and all other antibiotics combined) increased for pharmacists and physicians over the study timeframe. Pharmacist prescribing for all other antibiotics remained low over the study timeframe (1.27–1.57 per 1000 inhabitants per year), but physician prescribing increased from 211.47 (2022) to 239.07 (2023) and 259.47 (2024) per 1000 inhabitants per year. This was driven by increases in physician-prescribing rates for penicillin without β-lactamase inhibitors (eg, amoxicillin), penicillin with β-lactamase inhibitors (eg, amoxicillin-clavulanate) and macrolides (eg, azithromycin, clarithromycin) (table 2). Interpretation This retrospective study during the first year of the programme using pharmacist billing and prescription data showed an initial and high demand for the service followed by a gradual increase in pharmacist billing claims for UTI and tick bites 24 months after policy implementation. While most visits resulted in a prescription being issued, 10–15% of these assessments did not. In the post-implementation period, pharmacist-prescribing rates sharply increased for eligible urinary antibiotics in females and for doxycycline but not for other antibiotics. During the same timeframe, physician-prescribing rates for eligible urinary antibiotics and urinary FQ in females decreased, as did their prescribing rate for doxycycline. The net effect of policy implementation appears to be a modest increase in the overall prescribing rate for eligible UTI antibiotics in females, a small decrease in prescribing rate for urinary FQ in females and no change for doxycycline. There was no change in pharmacist prescribing of other ineligible antibiotics, which remained low across all 3 years; this is expected and reflects pharmacists’ practice of adapting prescriptions (ie, altering dose, dosage form, regimen or route of administration) or renewing prescriptions for continuity of care, which results in the pharmacist being designated as the prescriber.20 21 Previous evaluations of pharmacist antibiotic-prescribing practices in other jurisdictions have described benefits to patients and the healthcare system as well as the emerging role of community pharmacists in antimicrobial stewardship.10 Despite this, there continues to be concerns that allowing pharmacists to prescribe antibiotics for uncomplicated UTI and LD prophylaxis in Ontario could result in suboptimal patient care and overprescribing, potentially exacerbating negative downstream consequences such as antimicrobial resistance. Previous research conducted in New Brunswick showed antibiotic prescribing by pharmacists for uncomplicated UTI to be highly guideline concordant (95% vs 35% for physicians).11 12 The results of this study suggest that pharmacists are assessing patients and prescribing antibiotics within the defined policy limits. Nearly all billing claims for uncomplicated UTI were for females over 15 years of age, and there were no relevant changes in pharmacist prescribing for eligible urinary antibiotics in males or urinary FQ in females or males (which are currently out of scope for pharmacists). While our study identified a modest 10% increase in eligible urinary antibiotic prescribing in females, we also saw a small decrease in urinary FQ prescribing in females by physicians, an agent that should be reserved as second line for cystitis due to concerns regarding antimicrobial resistance and rare but debilitating adverse events related to tendinopathy, peripheral neuropathy and central nervous system effects.22 23 This net increase could reflect more appropriate selection of antibiotics resulting in a shift away from second-line agents (other than urinary FQ), increased prescribing of trimethoprim-sulfamethoxazole (an eligible urinary antibiotic) by physicians for non-urinary indications or increased pharmacist adaptations of eligible urinary antibiotic prescriptions as the result of drug shortages, particularly for nitrofurantoin in late 2024.24 Alternatively, this could also be related to improved access to UTI treatment or overprescribing for females with incorrect self-diagnosis of UTI. However, due to data limitations, we could not confirm these hypotheses. Although 70% of LD cases in Ontario are reported in June, July and August, the observed seasonal pattern of increased tick bite claims in the spring and fall months is consistent with the activity of adult blacklegged ticks. Compared with nymphs, which are very small and most active in summer, adult ticks are more likely to be detected by individuals who then present to healthcare providers for LD prophylaxis.25 Similar trends have also been observed in Nova Scotia.13 As expected, pharmacist-prescribing rates increased for doxycycline post policy implementation in Ontario; this was offset by decreased doxycycline prescribing by physicians, resulting in no net change. Pharmacist prescribing for all other antibiotics remained low pre- and post-implementation. Total community antibiotic prescribing rates (ie, for all antibiotics, physician and pharmacist combined) increased from 297.1 per 1000 inhabitants in 2022 to 333.4 in 2023 and 355.8 in 2024, which reflects reversion to pre-pandemic prescribing rates. The total antibiotic-prescribing rate was higher in 2019 than in 2024 at 369.9 per 1000 inhabitants, but prescribing rates decreased during the pandemic due to less prescribing for respiratory indications.26 27 Increased prescribing rates for other non-urinary antibiotics in 2023 and 2024 were driven by penicillins without B-lactamase inhibitors, penicillins with B-lactamase inhibitors and macrolides which are antibiotics typically used for respiratory infections and not relevant to the policy of interest. Several limitations of this study should be highlighted. First, these data may underestimate the number of visits as they do not capture visits where pharmacists referred or assessed an individual without claiming a fee. This would include situations where individuals are not eligible for Ministry-funded services or have exceeded the maximum number of assessments per condition per year eligible for funding.6 The antibiotic prescription data provide prescription counts stratified by antibiotic class, patient age and sex but lack other details such as the duration of therapy or intended indication, thereby limiting the evaluation of appropriateness. For example, without this information, we were unable to segment prescriptions for single-dose doxycycline from longer courses of doxycycline prescribed for indications other than LD prophylaxis. Additionally, the use of administrative data from two distinct sources that could not be linked at the patient or prescriber level excluded the assessment of impact of this policy on other healthcare visits (ie, outpatient clinic and/or emergency department) for UTI. Finally, while our ITS models accounted for underlying time trends and seasonality, residual temporal and non-temporal confounding is possible. Conclusion Based on these data, pharmacists in Ontario appear to be prescribing antibiotics within the defined policy limits for uncomplicated UTI and LD prophylaxis. While we observed a small increase in total prescribing of eligible antibiotics in females after policy implementation, we did not find any other signals of increased overall antibiotic prescribing beyond expected post-pandemic trends, which appear to be driven by physician prescribing of other antibiotics. Future work should focus on opportunities to further support pharmacists in prescribing antibiotics appropriately, particularly as pharmacists gain additional antibiotic-prescribing authority; this may include appropriate limitations to scope (ie, to first-line treatment options and/or specific patient criteria) as there are with uncomplicated UTI and tick bite prophylaxis and continuing education on antimicrobial stewardship. Policymakers can also address overprescribing concerns through ongoing evaluation and surveillance. The statements, findings, conclusions, views and opinions expressed in this report are based in part on data obtained under licence from IQVIA Solutions Canada Inc. concerning the following information service(s): GPM, from: 1 January 2022 to 31 December 2024. All rights reserved. The statements, findings, conclusions, views and opinions expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities. Footnotes Funding: This project was completed as part of the authors’ routine work. Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-107109). Data availability free text: Data sharing: the pharmacist claims the data set from this study is held securely in coded form at ICES. Although legal data-sharing agreements between ICES and data providers (eg, healthcare organisations and government) prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at https://www.ices.on.ca/DAS (email: das@ices.on.ca). The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programmes may rely on coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification. The antimicrobial prescribing data set used for this study is publicly available on the Ontario Antimicrobial Stewardship Program & Antimicrobial Resistance Comparison Tool: https://www.publichealthontario.ca/en/Health-Topics/Antimicrobial-Stewardship/ASP-Comparison-Tool?tab=community. Patient consent for publication: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Data availability statement Data are available in a public, open access repository. Data may be obtained from a third party and are not publicly available. References Data Availability Statement Data are available in a public, open access repository. Data may be obtained from a third party and are not publicly available.